89bio is a biopharmaceutical company that develops therapies for liver and cardio-metabolic diseases. Its main candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis and severe hypertriglyceridemia. The company is based in San Francisco and was founded in 2018.